One March 22, 2016 the Food and Drug Administration (FDA) has expanded the approved uses of the targeted therapy crizotinib (Xalkori®) for patients with non-small cell lung cancer (NSCLC).
The new approval is for the treatment of patients with advanced NSCLC whose tumors have alterations—known as rearrangements—in the ROS1 gene. Crizotinib was originally approved for patients with advanced NSCLC whose tumors have similar alterations in the ALK gene. Read more here.
No comments:
Post a Comment